Bailard Inc. Sells 2,166 Shares of Edwards Lifesciences Co. (NYSE:EW)

Bailard Inc. decreased its position in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 3.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,342 shares of the medical research company’s stock after selling 2,166 shares during the quarter. Bailard Inc.’s holdings in Edwards Lifesciences were worth $8,595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in EW. CX Institutional boosted its holdings in shares of Edwards Lifesciences by 7.7% in the 3rd quarter. CX Institutional now owns 1,243 shares of the medical research company’s stock worth $141,000 after purchasing an additional 89 shares during the period. McIlrath & Eck LLC boosted its holdings in Edwards Lifesciences by 7.2% during the 4th quarter. McIlrath & Eck LLC now owns 1,584 shares of the medical research company’s stock valued at $205,000 after acquiring an additional 106 shares during the period. J.W. Cole Advisors Inc. boosted its holdings in Edwards Lifesciences by 3.7% during the 4th quarter. J.W. Cole Advisors Inc. now owns 3,194 shares of the medical research company’s stock valued at $414,000 after acquiring an additional 114 shares during the period. Souders Financial Advisors boosted its holdings in Edwards Lifesciences by 2.0% during the 4th quarter. Souders Financial Advisors now owns 5,913 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 115 shares during the period. Finally, Balasa Dinverno & Foltz LLC boosted its holdings in Edwards Lifesciences by 1.9% during the 4th quarter. Balasa Dinverno & Foltz LLC now owns 6,295 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 118 shares during the period. 82.54% of the stock is currently owned by institutional investors and hedge funds.

In other Edwards Lifesciences news, VP Larry L. Wood sold 7,242 shares of the stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $96.13, for a total transaction of $696,173.46. Following the completion of the transaction, the vice president now owns 206,069 shares of the company’s stock, valued at $19,809,412.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 32,550 shares of the stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $110.09, for a total value of $3,583,429.50. The disclosure for this sale can be found here. Insiders have sold 282,581 shares of company stock worth $30,556,623 in the last quarter. 1.29% of the stock is currently owned by company insiders.

A number of equities analysts recently issued reports on the company. Stifel Nicolaus dropped their price objective on Edwards Lifesciences from $132.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, January 27th. Evercore ISI lowered their target price on Edwards Lifesciences from $130.00 to $122.00 and set an “outperform” rating for the company in a report on Thursday, January 27th. Wolfe Research started coverage on Edwards Lifesciences in a report on Tuesday, April 5th. They issued an “outperform” rating and a $134.00 target price for the company. Raymond James lowered their target price on Edwards Lifesciences from $134.00 to $126.00 and set an “outperform” rating for the company in a report on Thursday, January 27th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $132.00 to $135.00 in a report on Wednesday, March 16th. Five analysts have rated the stock with a hold rating and twenty-one have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $128.29.

Shares of EW traded up $4.11 during mid-day trading on Friday, reaching $97.55. The company had a trading volume of 2,569,677 shares, compared to its average volume of 3,178,006. Edwards Lifesciences Co. has a 52-week low of $88.01 and a 52-week high of $131.73. The company has a quick ratio of 2.64, a current ratio of 3.41 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $60.65 billion, a P/E ratio of 39.98, a PEG ratio of 2.82 and a beta of 1.16. The stock has a 50 day moving average of $112.06 and a two-hundred day moving average of $114.55.

Edwards Lifesciences (NYSE:EWGet Rating) last issued its earnings results on Tuesday, April 26th. The medical research company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. Edwards Lifesciences had a return on equity of 25.80% and a net margin of 28.72%. The firm had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the business earned $0.54 earnings per share. The company’s revenue was up 10.2% compared to the same quarter last year. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Edwards Lifesciences Company Profile (Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Recommended Stories

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.